GSK Says Headline Data From A Planned Interim Efficacy Analysis Of The DREAMM-7 Head-to-head Phase 3 Trial Of Belantamab Mafodotin For Relapsed Or Refractory Multiple Myeloma Met Its Primary Endpoint Of Progression-free Survival
Portfolio Pulse from Benzinga Newsdesk
GSK announced positive results from the DREAMM-7 Phase 3 trial of Belantamab Mafodotin for relapsed or refractory multiple myeloma, meeting its primary endpoint of progression-free survival. The treatment, combined with bortezomib and dexamethasone, showed a significant extension in time to disease progression or death compared to the standard of care, daratumumab with BorDex. Additionally, a notable overall survival trend was observed.
November 27, 2023 | 10:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's positive interim efficacy results from the DREAMM-7 trial could boost investor confidence, potentially leading to a short-term uptick in GSK's stock price due to the successful primary endpoint achievement and the strong overall survival trend.
The announcement of successful trial results typically has a positive impact on a pharmaceutical company's stock price, as it not only demonstrates progress in their pipeline but also increases the likelihood of regulatory approval and future revenue from the new treatment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100